European project backs Phase 2 trial of potential Parkinson’s therapy

HER-096 study plans to enroll about 100 people with newly diagnosed Parkinson's

Written by Andrea Lobo |

A stethoscope on a white surface with blue dollar signs and strings of binary code superimposed over the image.

A new €8 million European research project will support a Phase 2 trial of HER-096, an experimental therapy for Parkinson's disease. (Photo from iStock)

  • Parkinson's disease is a neurodegenerative condition involving the loss of dopamine-producing nerve cells, leading to motor symptoms like tremors and stiffness.
  • A European research project is backing a Phase 2 trial of HER-096, a therapy designed to protect nerve cells and potentially slow disease progression.
  • The upcoming multinational trial plans to enroll about 100 newly diagnosed patients to evaluate the therapy's safety and efficacy, using a smartphone-based score to measure motor performance.

A new €8 million (about $8.8 million) European research project will support a Phase 2 trial of HER-096, Herantis Pharma’s experimental therapy designed to protect nerve cells and potentially slow Parkinson’s disease progression.

The multinational study is expected to enroll about 100 people with newly diagnosed Parkinson’s at clinical centers across Europe. Researchers will assess the treatment’s safety and efficacy and explore digital tools that may help detect changes in movement and disease progression.

Recommended Reading
Digital illustration of a human brain dissolving into colorful particles against a dark green background.

New tool may identify Parkinson’s patients at risk of cognitive problems

Phase 2 trial expected to begin in 2027

Preparations are underway, with plans to submit the clinical trial application by the end of the year. The first participant is expected to receive treatment in the first half of 2027, subject to financing and regulatory approvals.

The project, called HERMOD (HER-096 Motor Outcomes and Disease Modification in Parkinson’s Disease), is funded through the European Union’s Horizon Europe research and innovation program. It brings together clinical, academic, and industry partners across Europe to advance the clinical development of HER-096.

“We are pleased to launch HERMOD and begin the next stage in the clinical development of HER-096. This project will help us evaluate the potential of HER-096 in people with Parkinson’s disease and generate important evidence to support future development decisions,” Antti Vuolanto, Herantis’ CEO, said in a company press release.

Parkinson’s disease involves the progressive loss of dopaminergic neurons, nerve cells that produce dopamine, a chemical messenger that helps control movement. This leads to motor symptoms such as tremors, muscle stiffness, and slowed movement. Although available treatments can help manage symptoms, therapies that can slow or stop disease progression are still needed.

HER-096 is a small, lab-made derivative of cerebral dopamine neurotrophic factor (CDNF), a naturally occurring protein that helps nerve cells survive and recover. CDNF is found in blood and cerebrospinal fluid (CSF), the liquid surrounding the brain and spinal cord. HER-096 is designed to mimic CDNF’s biological activity and can be given by injection under the skin.

In preclinical studies, HER-096 showed neuroprotective effects on dopaminergic neurons and affected biological processes involved in protein regulation, cellular energy production, and inflammation.

Earlier HER-096 trial showed promising safety findings

In a Phase 1b trial (NCT06659562), HER-096 was well tolerated in healthy volunteers. After a single 300 mg injection, HER-096 levels in the CSF exceeded the minimum target range established from preclinical data. These findings supported a dosing schedule of two or three times a week.

The trial also included people with Parkinson’s who were randomly assigned to receive 200 mg or 300 mg of HER-096, or a placebo, twice a week for four weeks. The treatment was generally well tolerated, with adverse events mainly involving mild-to-moderate injection-site reactions.

Biomarker analyses also identified changes associated with three biological processes: proteostasis, mitochondrial function, and neuroinflammation. Proteostasis involves processes that manage how proteins are produced, folded, and cleared, while mitochondrial function helps cells meet their energy needs. Neuroinflammation refers to inflammation in the nervous system. These findings were consistent with the treatment’s proposed mechanism of action.

In the Phase 2 study, participants will be randomly assigned to receive HER-096 or a placebo for 36 weeks, or about nine months. All participants will then receive HER-096 for 24 weeks.

The study will evaluate the therapy’s efficacy, safety, and tolerability. Researchers will also explore digital biomarkers that may detect changes in motor function and disease progression more sensitively than conventional assessments. The planned primary efficacy measure is a smartphone-based Digital Motor Score, which objectively tracks motor performance.

“HERMOD brings together complementary expertise across Europe to evaluate and advance a promising investigational therapy for Parkinson’s disease. By combining scientific excellence, clinical expertise and cross-sector collaboration, we aim to generate knowledge that may help improve the lives of people living with this condition,” said Rejko Krüger, MD, principal investigator at Luxembourg Institute of Health and Centre Hospitalier de Luxembourg.

The project is coordinated by Karolinska University Hospital in Sweden, while Herantis Pharma sponsors the clinical trial and leads its scientific and technical implementation. Clinical sites are planned in Sweden and Luxembourg, with additional sites outside the EU-funded consortium also expected to participate.

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.